JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB28274

Anti-ADAMTS13 antibody

4

(1 Review)

|

(5 Publications)

Rabbit Polyclonal ADAMTS13 antibody. Suitable for WB and reacts with Human samples. Cited in 5 publications. Immunogen corresponding to Synthetic Peptide within Human ADAMTS13.

View Alternative Names

C9orf8, UNQ6102/PRO20085, ADAMTS13, A disintegrin and metalloproteinase with thrombospondin motifs 13, ADAM-TS 13, ADAM-TS13, ADAMTS-13, von Willebrand factor-cleaving protease, vWF-CP, vWF-cleaving protease

1 Images
Western blot - Anti-ADAMTS13 antibody (AB28274)
  • WB

Unknown

Western blot - Anti-ADAMTS13 antibody (AB28274)

Glycosylation and the abundance of cysteine residues gives ADAMTS-13 an apparent molecular weight of about 190 kDa on reduced SDS PAGE gels.

All lanes:

Western blot - Anti-ADAMTS13 antibody (ab28274) at 1 µg/mL

Lane 1:

Recombinant Human ATS-13 at 0.08 µg

Lane 2:

Recombinant Human ATS-13 at 0.04 µg

Lane 3:

Recombinant Human ATS-13 at 0.02 µg

Predicted band size: 154 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB

applications

Immunogen

Synthetic Peptide within Human ADAMTS13. The exact immunogen used to generate this antibody is proprietary information.

Q76LX8

Specificity

<p>ab28274 recognises the metalloproteinase domain of ADAMTS13&#46;</p>

style
left-column

Alternative Products

Primary Antibodies

AB177940

Anti-ADAMTS13 antibody [EPR6132]

RabMAb|Recombinant

Flow Cytometry (Intracellular) - Anti-ADAMTS13 antibody [EPR6132] (AB177940)

  • 0
  • 0
Primary Antibodies

AB90786

Anti-ADAMTS13 antibody [20A5]

  • 0
  • 0
Primary Antibodies

AB72335

Anti-ADAMTS13 antibody

Immunoprecipitation - Anti-ADAMTS13 antibody (AB72335)

  • 0
  • 0
Primary Antibodies

AB264161

Anti-ADAMTS13 antibody

Immunoprecipitation - Anti-ADAMTS13 antibody (AB264161)

  • 0
  • 0
Primary Antibodies

AB28273

Anti-ADAMTS13 antibody

Immunocytochemistry/ Immunofluorescence - Anti-ADAMTS13 antibody (AB28273)

  • 0
  • 0
Primary Antibodies

AB264162

Anti-ADAMTS13 antibody

Immunoprecipitation - Anti-ADAMTS13 antibody (AB264162)

  • 0
  • 0
Primary Antibodies

AB71550

Anti-ADAMTS13 antibody

  • 4
  • 1

Complementary Products

Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20
Primary Antibodies

AB7817

Anti-alpha smooth muscle Actin antibody [1A4]

KO Validated

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-alpha smooth muscle Actin antibody [1A4] (AB7817)

  • 5
  • 105
Primary Antibodies

AB157469

Anti-Tissue Plasminogen Activator antibody [EPR7232(2)]

20ul selling size|BOND RX™ Validated|RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Tissue Plasminogen Activator antibody [EPR7232(2)] (AB157469)

  • 3
  • 1
Primary Antibodies

AB316979

Anti-Von Willebrand Factor antibody [RM1068]

BOND RX™ Validated|20ul selling size|Recombinant|RabMAb

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Von Willebrand Factor antibody [RM1068] (AB316979)

  • 0
  • 1
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/5000", "WB-species-notes": "<p>1/1000 when using colorimetric substrates such as BCIP/NBT - 1/5000, when using chemiluminescent substrates. Glycosylation and the abundance of cysteine residues gives ADAMTS 13 an apparent molecular weight of 190 kDa on reduced SDS PAGE gels. Several bands at 110-190 kDa are observed on Western blots, possibly indicating differentially processed ADAMTS 13. Dilution optimised using Chromogenic detection.</p>" }, "Mouse": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Rat": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" } } }
style
left-column
style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Storage buffer
pH: 7.4 Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ADAMTS13 also known as von Willebrand factor-cleaving protease (VWFCP) is a zinc-containing metalloprotease with a molecular mass of approximately 190 kDa. This protein belongs to the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family and exhibits a complex structure with specific domains including a metalloprotease and a disintegrin-like domain. ADAMTS13 is produced mainly in the liver and circulates in the blood plasma. Research shows that it primarily facilitates the cleavage of von Willebrand factor (vWF) a large multimeric protein essential for blood clotting.
Biological function summary

ADAMTS13 plays a role in regulating the size and function of von Willebrand factor (vWF) ensuring proper hemostatic balance. The enzyme prevents the accumulation of ultra-large vWF multimers which can lead to spontaneous platelet aggregation and thrombus formation. Although ADAMTS13 acts independently its function is closely linked to the dynamics of vWF in response to vascular injury. Properly functioning ADAMTS13 aids in maintaining normal blood flow by preventing unnecessary clot formation in the bloodstream.

Pathways

ADAMTS13 is critical in the coagulation and hemostatic pathways. It operates by modulating the activity of vWF which plays an essential role in platelet adhesion and aggregation forming part of the coagulation cascade. A significant relationship exists between ADAMTS13 and vWF in these pathways as the protease controls vWF multimer size directly impacting clot formation. In the context of hemostatic balance ADAMTS13 intersects with factors like thrombin and fibrinogen which further contribute to clotting processes.

ADAMTS13 deficiency or dysfunction is associated with thrombotic thrombocytopenic purpura (TTP) a rare but severe blood disorder. In TTP the reduced activity of ADAMTS13 leads to an over-accumulation of ultra-large vWF multimers resulting in excessive platelet aggregation and microvascular thrombosis. Another related condition is atypical hemolytic uremic syndrome (aHUS) where abnormal ADAMTS13 activity might exacerbate the disease pathology. Both disorders highlight the critical need for balanced ADAMTS13 function in maintaining vascular health and highlight its potential as a therapeutic target.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Cleaves the vWF multimers in plasma into smaller forms thereby controlling vWF-mediated platelet thrombus formation.
See full target information ADAMTS13
style
left-column

Publications (5)

Recent publications for all applications. Explore the full list and refine your search

Scientific reports 14:9073 PubMed38643218

2024

Optimization of plasma-based BioID identifies plasminogen as a ligand of ADAMTS13.

Applications

Unspecified application

Species

Unspecified reactive species

Hasam Madarati,Veronica DeYoung,Kanwal Singh,Taylor Sparring,Andrew C Kwong,James C Fredenburgh,Cherie Teney,Marlys L Koschinsky,Michael B Boffa,Jeffrey I Weitz,Colin A Kretz

Molecules (Basel, Switzerland) 27: PubMed36144730

2022

Differential Expression and Localization of ADAMTS Proteinases in Proliferative Diabetic Retinopathy.

Applications

Unspecified application

Species

Unspecified reactive species

Ahmed M Abu El-Asrar,Mohd Imtiaz Nawaz,Eef Allegaert,Mohammad Mairaj Siddiquei,Ajmal Ahmad,Priscilla Gikandi,Gert De Hertogh,Ghislain Opdenakker

Frontiers in medicine 4:232 PubMed29326937

2017

Removal of the C-Terminal Domains of ADAMTS13 by Activated Coagulation Factor XI induces Platelet Adhesion on Endothelial Cells under Flow Conditions.

Applications

WB

Species

Unspecified reactive species

Kathleen S Garland,Stéphanie E Reitsma,Toshiaki Shirai,Jevgenia Zilberman-Rudenko,Erik I Tucker,David Gailani,András Gruber,Owen J T McCarty,Cristina Puy

Molecular medicine reports 11:3015-20 PubMed25482054

2014

Changes in von Willebrand factor and ADAMTS-13 in patients following arthroplasty.

Applications

Unspecified application

Species

Unspecified reactive species

Ling Liu,Jing Ling,Zhenni Ma,Quan Yuan,Jun Pan,Huilin Yang

Neuroscience letters 517:1-6 PubMed22425718

2012

ADAMTS-13 is produced by glial cells and upregulated after spinal cord injury.

Applications

Unspecified application

Species

Unspecified reactive species

Ryoji Tauchi,Shiro Imagama,Tomohiro Ohgomori,Takamitsu Natori,Ryuichi Shinjo,Naoki Ishiguro,Kenji Kadomatsu
View all publications
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com